Article Text

Download PDFPDF
Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma
  1. C Hughes1,
  2. A Murphy2,
  3. C Martin3,
  4. E Fox4,
  5. M Ring3,
  6. O Sheils3,
  7. B Loftus2,
  8. J O’Leary3
  1. 1Histopathology Department, John Radcliffe Hospital, Headington, Oxford, UK
  2. 2Department of Pathology, Adelaide and Meath Hospital Incorporating the National Children’s Hospital, and Trinity College, Dublin, Ireland
  3. 3Department of Pathology, Coombe Women’s Hospital, and Trinity College Dublin
  4. 4Department of Pathology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin
  1. Correspondence to:
 Dr C Hughes
 Histopathology Department, John Radcliffe Hospital, Headington, Oxford OX3 9DZ, UK;{at}


Aim: To investigate and compare topoisomerase II-α expression in benign prostatic hyperplasia (BPH), prostate cancer of varying Gleason scores and hormone-insensitive prostate cancer.

Methods: The immunohistochemical expression of topoisomerase II-α antibody in the above-mentioned diagnostic categories was investigated and compared.

Results: Increased expression of topoisomerase II-α was seen in the prostate cancers of Gleason scores 7 and 8–10 (p = 0.000) compared with prostate cancers of Gleason score 6 and BPH (p = 0.245). Statistically significant differences were found in the topoisomerase II-α gene expression between prostate cancers categorised by Gleason Score. Also, increased expression of topoisomerase II-α was seen in the known hormone-resistant prostate carcinomas compared with prostate cancers with no hormone treatment in the subgroup with Gleason scores 8–10, which approached statistical significance (p = 0.081). No statistically significant difference was observed in topoisomerase II-α expression between the groups with BPH and prostate carcinoma of Gleason score 6 (p = 0.245).

Conclusion: Topoisomerase II-α expression was found to increase with the known prognostic marker Gleason score and with hormone insensitivity. Objective evidence is provided for clinical trials with drugs targeting topoisomerase II-α to be targeted to patients with prostate cancers of Gleason Score >6 and, in particular, prostate cancers of Gleason Scores 8–10.

  • BPH, benign prostatic hyperplasia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.